Cellectar Biosciences, Inc. (CLRB)

NASDAQ: CLRB · IEX Real-Time Price · USD
3.880
+0.390 (11.17%)
At close: Feb 27, 2024, 4:00 PM
3.940
+0.060 (1.55%)
After-hours: Feb 27, 2024, 7:59 PM EST
11.17%
Market Cap 42.89M
Revenue (ttm) n/a
Net Income (ttm) -37.75M
Shares Out 12.29M
EPS (ttm) -3.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,951,494
Open 3.570
Previous Close 3.490
Day's Range 3.540 - 3.950
52-Week Range 1.300 - 4.380
Beta 0.94
Analysts n/a
Price Target n/a
Earnings Date Mar 7, 2024

About CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 15
Stock Exchange NASDAQ
Ticker Symbol CLRB
Full Company Profile

Financial Performance

Financial Statements

News

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commerciali...

20 days ago - GlobeNewsWire

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health's National Cancer Institute (NCI) Study of Iopofosine I 131 Supported by $2 Million Grant from the Nationa...

4 weeks ago - GlobeNewsWire

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...

4 weeks ago - GlobeNewsWire

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient

Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies Io...

5 weeks ago - GlobeNewsWire

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study FLORHAM PARK, N.J., Jan. 16...

6 weeks ago - GlobeNewsWire

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D.

Dr. Levy to Provide Perspective on Iopofosine I 131's Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia Dr. Levy to Provide Perspective on Iopofosine I 131's Pot...

6 weeks ago - GlobeNewsWire

Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy Partnership to Provide Key Data on WM Treatment Landscape a...

6 weeks ago - GlobeNewsWire

Cellectar's blood cancer therapy succeeds in trial

Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines...

7 weeks ago - Reuters

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...

7 weeks ago - GlobeNewsWire

Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation

Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments Exclusive License Agreement to Develop and Commercialize Pediatric Cancer Treatments

2 months ago - GlobeNewsWire

Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform

Expanded Global Patent Provides Protection for Phospholipid Drug Conjugate™ (PDC) Platform to Deliver Flavaglines as Targeted Anticancer Payloads Expanded Global Patent Provides Protection for Phospho...

2 months ago - GlobeNewsWire

Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe

FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...

3 months ago - GlobeNewsWire

Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024

Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 (GLOBE NEWSWI...

4 months ago - GlobeNewsWire

Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ...

5 months ago - GlobeNewsWire

Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

The EMA's PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options The EMA's PRIME status is gran...

5 months ago - GlobeNewsWire

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing

FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commerciali...

6 months ago - GlobeNewsWire

Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors

6 months ago - GlobeNewsWire

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

7 months ago - GlobeNewsWire

Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting

Interim data from 64 refractory multiple myeloma patients demonstrated an ORR of 28%, a CBR of 70%, and a DCR of 92%

8 months ago - GlobeNewsWire

Cellectar Provides a Research and Development Program Summary

Waldenstrom's macroglobulinemia pivotal trial top-line data now expected second half of 2023; pediatric high-grade glioma trial to initiate in Q3

9 months ago - GlobeNewsWire

UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of t...

10 months ago - GlobeNewsWire

Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of t...

10 months ago - GlobeNewsWire

Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update

FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of...

1 year ago - GlobeNewsWire

Cellectar to Participate at Upcoming Banking Conferences

FLORHAM PARK, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial...

1 year ago - GlobeNewsWire

Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient

Response Achieved in Primary Central Nervous System Lymphoma for which there is no Approved Treatment Response Achieved in Primary Central Nervous System Lymphoma for which there is no Approved Treatm...

1 year ago - GlobeNewsWire